AVERSA Technology Platform
Abuse-deterrent formulation for other transdermal opioids & drugs with abuse potential
Key Facts
About Nutriband
Nutriband Inc. is a US-based biopharmaceutical company focused on developing and commercializing advanced transdermal drug delivery technologies. Its strategic achievements include the acquisition of clinical subsidiary 4P Therapeutics, establishing a robust patent portfolio for its flagship AVERSA abuse-deterrent platform, and building a hybrid business model with contract manufacturing and consumer product revenue streams. The company's strategy is to first bring an abuse-deterrent fentanyl patch to market, followed by expanding the AVERSA technology to other high-risk drugs and leveraging its transdermal expertise to convert injectable biologics into patch-based therapies.
View full company profile